Stay updated with breaking news from Integrin Inhibitor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) has received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target […]
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 568,400 shares, an increase of 102.8% from the April 30th total of 280,300 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average […]
StockNews.com upgraded shares of Clearside Biomedical (NASDAQ:CLSD – Get Rating) from a sell rating to a hold rating in a research report released on Wednesday. Several other research firms have also recently weighed in on CLSD. 500.com reissued a reiterates rating on shares of Clearside Biomedical in a research note on Friday, April 28th. HC […]
StockNews.com upgraded shares of Clearside Biomedical (NASDAQ:CLSD – Get Rating) from a sell rating to a hold rating in a research note released on Wednesday. Other research analysts also recently issued reports about the company. 500.com reiterated a reiterates rating on shares of Clearside Biomedical in a research report on Friday, April 28th. JMP Securities […]
StockNews.com cut shares of Clearside Biomedical (NASDAQ:CLSD – Get Rating) from a hold rating to a sell rating in a research report released on Tuesday morning. CLSD has been the subject of several other research reports. Needham & Company LLC restated a buy rating and set a $4.00 price target on shares of Clearside Biomedical […]